Change is afoot at the helm of international pharma company Sanofi, as it announces the departure of a key leadership figure from its research and development team.
In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in ser
Eli Lilly has named Thomas Fuchs as its first-ever chief artificial intelligence officer (CAIO), bolstering the digital representation in the group's C-suite.
